Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-20 19:06 CEST (UTC+2h)

Non-compartmental analysis [Regulatives / Guidelines]

posted by M.tareq - 2017-12-31 17:17  - Posting: # 18130
Views: 804

Dear all,

As per guidelines "Non-compartmental methods should be used for determination of pharmacokinetic parameters in
bioequivalence studies. The use of compartmental methods for the estimation of parameters is not

why the non-Compartmental analysis is preferred over compartmental ones ?

also use of PK/PD models to establish BE, as per my understanding BE is about detecting differences between formulations in healthy volunteers and from that, it can be extended to patients population.

PK/PD models can't be used to detect such differences? and conclude BE?

Also regarding use of pop/INDV BE, most FDA OGD drafts revolve around use of average BE in most cases and in case of HVDP, reference scaling and/or variability comparison -for FDA and SCABEL for EMA- is preferred due to number of subjects that would be needed.

when pop/indv BE is feasible or applicable? does the nature of the drug molecule determine such approach? also any published BE studies based on either of them.

Thanks in advance.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,191 registered users;
online 22 (1 registered, 21 guests [including 12 identified bots]).

If there is an exception to any rule,
and if it can be proved by observation,
that rule is wrong.    Richard Feynman

BEBAC Ing. Helmut Schütz